Literature DB >> 7826293

The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial.

.   

Abstract

OBJECTIVE: To determine the magnitude of the decrease in the risk of retinopathy progression observed with intensive treatment and its relationship to baseline retinopathy severity and duration of follow-up.
DESIGN: Randomized clinical trial, with 3 to 9 years of follow-up. SETTING AND PATIENTS: Between 1983 and 1989, 29 centers enrolled 1441 patients with insulin-dependent diabetes mellitus aged 13 to 39 years, including 726 patients with no retinopathy and a duration of diabetes of 1 to 5 years (primary prevention cohort) and 715 patients with very mild to moderate nonproliferative diabetic retinopathy and a duration of diabetes of 1 to 15 years (secondary intervention cohort). Ninety-five percent of all scheduled examinations were completed.
INTERVENTIONS: Intensive treatment consisted of the administration of insulin at least three times a day by injection or pump, with doses adjusted based on self-blood glucose monitoring and with the goal of normoglycemia. Conventional treatment consisted of one or two daily insulin injections. OUTCOME MEASURES: Change between baseline and follow-up visits on the Early Treatment Diabetic Retinopathy Study retinopathy severity scale, assessed with masked gradings of stereoscopic color fundus photographs obtained every 6 months.
RESULTS: Cumulative 8.5-year rates of retinopathy progression by three or more steps at two consecutive visits were 54.1% with conventional treatment and 11.5% with intensive treatment in the primary prevention cohort and 49.2% and 17.1% in the secondary intervention cohort. At the 6- and 12-month visits, a small adverse effect of intensive treatment was noted ("early worsening"), followed by a beneficial effect that increased in magnitude with time. Beyond 3.5 years of follow-up, the risk of progression was five or more times lower with intensive treatment than with conventional treatment. Once progression occurred, subsequent recovery was at least two times more likely with intensive treatment than with conventional treatment. Treatment effects were similar in all baseline retinopathy severity subgroups.
CONCLUSIONS: The results of the Diabetes Control and Complications Trial strongly support the recommendation that most patients with insulin-dependent diabetes mellitus use intensive treatment, aiming for levels of glycemia as close to the nondiabetic range as is safely possible.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7826293     DOI: 10.1001/archopht.1995.01100010038019

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  94 in total

1.  Blood pressure control and diabetic retinopathy.

Authors:  R Klein; B E K Klein
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Long-term progression of retinopathy after initiation of insulin therapy in Type 2 diabetes: an observational study.

Authors:  C S Arun; R Pandit; R Taylor
Journal:  Diabetologia       Date:  2004-07-28       Impact factor: 10.122

Review 3.  Does familial clustering of risk factors for long-term diabetic complications leave any place for genes that act independently?

Authors:  Andrew D Paterson; Shelley B Bull
Journal:  J Cardiovasc Transl Res       Date:  2012-06-23       Impact factor: 4.132

Review 4.  Screening for diabetic retinopathy and diabetic macular edema in the United Kingdom.

Authors:  Tunde Peto; Christine Tadros
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

5.  There is level 1 evidence for intensive glycemic control for reducing the progression of diabetic retinopathy in persons with type 2 diabetes.

Authors:  Emily Y Chew
Journal:  Endocrine       Date:  2015-02-27       Impact factor: 3.633

6.  The accuracy of digital-video retinal imaging to screen for diabetic retinopathy: an analysis of two digital-video retinal imaging systems using standard stereoscopic seven-field photography and dilated clinical examination as reference standards.

Authors:  Mary Gilbert Lawrence
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.

Authors:  Jesús Ruberte; Eduard Ayuso; Marc Navarro; Ana Carretero; Víctor Nacher; Virginia Haurigot; Mónica George; Cristina Llombart; Alba Casellas; Cristina Costa; Assumpció Bosch; Fatima Bosch
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.

Authors:  Neil M Bressler; Allison R Edwards; Roy W Beck; Christina J Flaxel; Adam R Glassman; Michael S Ip; Craig Kollman; Baruch D Kuppermann; Thomas W Stone
Journal:  Arch Ophthalmol       Date:  2009-12

Review 9.  Fenofibrate and Diabetic Retinopathy.

Authors:  Jared E Knickelbein; Akshar B Abbott; Emily Y Chew
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

10.  [Diagnosis, therapy and follow up of diabetic eye disease].

Authors:  Michael Stur; Stefan Egger; Anton Haas; Gerhard Kieselbach; Stefan Mennel; Reinhard Michl; Michael Roden; Ulrike Stolba; Andreas Wedrich
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.